
    
      Inclusion Criteria:

        1. Patients aged 18 years -75 years, male or female;

        2. histologically or cytologically confirmed non-small cell lung cancer;

        3. consistent with the indication of chemotherapy

        4. the decrease of platelets appeared in the screen chemotherapy period and the platelet
           count is less than 50 * 109/ L;

        5. the expected survival was more than 3 months;

        6. patients must have the ability to understand and the willingness to sign a written
           informed consent;

        7. to be able to follow the study and follow-up procedures

      Exclusion Criteria:

        1. pregnant or lactating women;

        2. patients who had severe allergic history on biological preparation;

        3. the existing serious acute infection without control;

        4. Patients receiving radiotherapy;

        5. more than 3 metastatic tumor of bone were found in the screening period, and the
           platelet count did not restore to 100 * 109/ L on the screening period on the
           seventeenth day of the screening period;

        6. with a history of pulmonary embolism, myocardial infarction patients, thrombus history
           of thrombosis or activity in the past 3 months;

        7. Sepsis, disseminated intravascular coagulation (DIC); hypersplenism or any other illness
           sickness that can exacerbate thrombocytopenia appeared in the previous cycles of
           chemotherapy;

        8. tumor metastasis was found in the central nervous system;
    
  